A Phase I Study of Orally-administered AZD5213 in Healthy Males and Non-fertile Females Including Randomized, Double-blind, Placebo-controlled, Parallel-group Assessment of the Safety, Tolerability and PK of Single Ascending Dose (Part 1) and an Open-label Assessment of Effect of Food on the PK (Part 2).
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2016
At a glance
- Drugs AZD 5213 (Primary)
- Indications Alzheimer's disease; Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 07 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Dec 2010 Planned End Date changed from 1 Aug 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 10 Jun 2010 Actual end date changed from 1 Jun 20010 to 1 May 2010 as reported by ClinicalTrials.gov.